PPARA and fatty liver disease: In contrast, treatment with a Pparα agonist in HFD-fed USP25 KO mice did not alleviate metabolic phenotypes (Fig. 5, H–K) or hepatic steatosis (Fig. 5L), as confirmed by histological analysis, likely due to decreased Pparα levels.